HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Steripod Bolt-on Deal Extends Perrigo Into Toothbrush and Razor Accessories

Executive Summary

Perrigo's Ranir division purchased the brand, which includes a portfolio of antibacterial toothbrush protectors, children’s products and tongue cleaners, for an undisclosed amount from Bonfit America.

You may also be interested in...



Perrigo Oral Care Targets North American Value Tier With High Ridge Brands Buy

REACH and Dr. Fresh, as well as Firefly kids’ toothbrushes and mouth rinses featuring popular comic book and cartoon characters, will join Perrigo’s Ranir division under the $113m cash deal, which is subject to federal bankruptcy court approval but expected to close in the 2020 first quarter.

Perrigo Exploring The CBD Opportunity

Perrigo doesn't want to miss out on the opportunity presented by CBD to offer consumers a new type of self-care product, according to the firm’s managing director, UK & Ireland, and International vice president, Neil Lister.

Ranir Oral Care Deal Could Brighten Perrigo's Turnaround Chances

Ranir has a portfolio of more than 300 oral care solutions including power toothbrushes and heads, whitening strips, manual toothbrushes, floss, dentures and travel kits that it provides to retailers and other distributors in more than 50 countries. Adding Ranir, says Perrigo CEO Murray Kessler, "illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories."

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel